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Sulfotransferases (SULTs) play an important role in the detoxification and bioactivation 
of endogenous compounds and xenobiotics. Studies on rat sulfotransferases had shown 
that SULT genes, like cytochrome P450 genes and other phase II enzymes such as UDP-
gluronosyltransferases (UGTs) and Glutathione S-transferases (GSTs), can be regulated 
by ligands that bind nuclear receptors. For human SULT genes, the regulation of human 
SULT2A1 expression is currently the best characterized. Many nuclear receptors such as 
PXR and VDR were observed to induce SULT2A1. In contrast, induction of human 
SULT1A3 by nuclear receptors has not been well studied. Thus, in this study, we 
systematically examined the induction of human SULT1A3 genes by a whole range of 
nuclear receptor ligands. Transient transfection of the SULT1A3 5’-flanking region / 
luciferase reporter construct showed that SULT1A3 was responsive to dexamethasone, 
prednisolone, β-Napthaflavone (BNF) and 3-methylcholanthrene (3-MC) in a 
concentration-dependent manner with maximal induction at 10-7M dexamethasone, 1µM 
prednisolone, 100nM BNF and 100nM 3-MC. In addition, induction by dexamethasone 
was dependent on the level of expression of the glucocorticoid receptor. However, the 
induction by BNF was not dependent on the level of expression of the aryl hydrocarbon 
receptor (AhR) and aryl hydrocarbon receptor nuclear translocator (ARNT). Analysis of 
the 5’-flanking region led to the identification of a putative glucocorticoid response 
element at position (-1211 to -1193) and 2 putative AhR/ARNT response element at 
positions -2795 to -2773 and –1550 to -1528 upstream of the transcription start site. 
Deletion or mutation of the glucocorticoid response element resulted in a loss of response. 
Yet only the putative AhR/ARNT response element at position -2795 to -2773 was 
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observed to cause a loss of promoter activities in the deletion and mutation studies. In 
summary, the data from this study shows that the human SULT1A3 gene is inducible by 
glucocorticoids through a glucocorticoid receptor-mediated mechanism and the 
glucocorticoid response element at position (-1211 to -1193) is necessary for this 
induction. Similarly, the human SULT1A3 gene is inducible by AhR activators although 
the mechanism is still not clear at this moment and the induction is through the 
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1.1 Drug metabolism 
Drug metabolism is the defense mechanism by which humans counter the continuous 
exposure to xenobiotics, a collective term that refers to foreign objects, drugs and 
pollutants. There are three major phases involved in the whole process. First, the 
compounds are subjected to hydrolysis, reduction or oxidation, and these are catalyzed by 
enzymes such as cytochrome P450. The main purpose of this step is to expose the 
functional group of the drugs or pollutants for its activity or further enzymatic change. 
The second phase is conjugation such as glucuronidation, sulfation, methylation, 
acetylation and glutathione conjugation. Through adding functional groups to the 
compounds, the hydrophilicity is strongly increased to facilitate the excretion of 
xenobiotics. The last phase is transportation of the xenobiotics out of cell which is 
facilitated by membrane channels and transporters such as ATP-Binding Cassette (ABC) 
proteins (Urquhart et al., 2007).   
The formation of sulfate conjugates is an important pathway for the biotransformation of 
many endogenous and exogenous compounds, including drugs, hormones and 
neurotransmitters (Coughtrie et al., 1994; Coughtrie et al., 1998). Sulfation increases the 
water solubility and hence the excretion of many of these compounds. However, in some 
instances, this process may result in highly reactive metabolites (Glatt, 2000). Sulfate 
conjugation is catalyzed by sulfotransferases (SULTs) which are encoded by members of 




1.2 Sulfotransferases (SULTs) 
The human sulfotransferases utilize 3’ phosphoadenosine 5’ phosphosulfate (PAPS) to 
add a sulfo-moiety onto the substrate. Sulfotransferases are categorized according to its 
cellular location and specificity towards different substrates. The membrane-bound or 
secretory sulfotransferases, which show functional correlation with growth and 
development are not discussed in this thesis although they share structural similarity with 
the cytosolic sulfotransferases (Negishi et al. 2001). The cytosolic SULTs are very 
important phase II xenobiotic metabolism enzymes which have been studied extensively 
over the last decades. A list of its members is shown below in table 1.   
Cytosolic sulfotransferases usually are found as hetero- and homodimers, with monomer 
molecular weights ranging from 30 to 36 kDa (Falany, 1991). However, in some plants 
and mammals, monomers can exist and are catalytically active (Takikawa et al, 1986). 
SULTs are single α/β globular proteins with five-stranded parallel β-sheets that 
composed of the PAPS-binding site and the core active site of the enzyme. Both sites are 
highly conserved, reflecting the significance of SULTs in cellular functions.  
SULT1A is a subfamily of the cytosolic sulfotransferases. Members of this subfamily are 
expressed in many tissues and share at least 90% homology (Ozawa et al., 1995; Zhu et 
al., 1993A). Despite this, SULT1A enzymes exhibit differences in substrate preferences. 
SULT1A1 which was previously known as P-phenolsulfotransferase (P-PST) has high 
affinity for phenolic compounds while SULT1A3 is a catecholamine sulfotransferase and 
was also called M-PST (Honma et al., 2001). SULT1B family was originally isolated 
from the thyroid and its main catalytic function is to sulfate thyroid hormone. SULT1C 
family mediates the activation of N-hydroxy-2-acetylaminofluorene (N-OH-AAF) 
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through sulfate formation. Estrogen is the key endogenous substrate for hSULT1E1, and 
similar sulfotransferases have been identified in other species including rat, mouse, 
guinea pig and bovine (Nagata and Yamazoe, 2000). 
The SULT2A and SULT2B family mainly catalyze the sulfation of alcohols and 
neurotransmitters such as 3β-hydroxysteroids. SULT2A enzymes are highly expressed in 
liver while SULT2B enzymes are expressed in the placenta. The hSULT2B1a and 
hSULT2B1b are two isoforms of SULT2B1, composing of 350 and 365 amino acids 
respectively.   
SULT4A1 is a novel human cytosolic sulfotransferase expressed in brain, it is suspected 
that SULT4A1 is involved in neurotransmitter sulfation, however, its substrate has not 






















Table 1  List of cytosolic Human SULT superfamily cloned and characterized to 
date 




L19999 Wilborn et al. 1993 
L10819 Zhu et al. 1993B 
L19955 Zhu et al. 1993A 
U09031 Zhu et al. 1993B 
X84654 Jones et al. 1995 
X78283 Ozawa et al. 1995 
U26309 Hwang et al. 1995 
hSULT1A1 
AJ007418 Dajani et al. 1998 
X78282 Ozawa et al. 1995 
U28169 Zhu et al. 1996 hSULT1A2 
U28170 Zhu et al. 1996 
L19956 Zhu et al. 1993A 
U08032 Wood et al. 1994 
L25275 Bernier et al. 1994B 
SULT1A 
hSULT1A3 
X84653 Jones et al. 1995 
D89479 Fujita et al. 1997 SULT1B hSULT1B1 U95726 Wang et al. 1998 
U66036 Her et al. 1997 
AB008164 Yoshinari et al. 1998 hSULT1C2 
AF026303 Yoshinari et al. 1998 SULT1C 
hSULT1C4 AF055584 Sakakibara et al.1998 
U08098 Aksoy et al. 1994 
S77383 Rubin et al. 1999 
SULT1 
SULT1E hSULT1E1 
Y11195 Falany et al. 1995 
U08024 Otterness et al. 1992 
U08025 Otterness et al. 1992 
S43859 Kong et al. 1992 
L02337 Kong et al. 1992 
X70222 Comer et al. 1993 
S53620 Comer et al. 1993 
SULT2A hSULT2A1 
X84816 Forbes et al. 1995 
hSULT2B1a U92314 Her et al. 1998 
SULT2 
SULT2B hSULT2B1b U92315 Her et al. 1998 
AF188698 Falany et al. 2000 




1.3 Nuclear receptors 
Nuclear receptors are a class of intracellular proteins that regulate the sensitizing of 
hormones and certain molecule. The cloning of these receptors took place mainly during 
the 1980s, which is far later than the discovery of the receptors and some of the 
endogenous substrates such as hormones. The significance of these receptors includes 
their roles in development, homeostasis, metabolism and specific-gene expression. Upon 
ligand-binding, the receptors translocate into the nucleus and bind to specific motifs on 
DNA, and transcriptionally regulate the expression of downstream targets (Figure 1.1). 
The dysfunction of nuclear receptor signaling can result in various metabolic disorders 





Figure 1.1: The mechanism of nuclear receptors (NR) actions  
Binding of the hormone or ligands to the Nuclear Receptor/Heat Shock Protein complex 
(NR/HSP) will lead to the dissociation of HSP. The nuclear receptor will dimerize and 
translocate into the nuclear receptor, binding to hormone response element (HRE), and 
transcriptionally regulate the gene expression. 
 
Nuclear receptor proteins usually comprise of 5 domains: N-terminal regulatory domain, 
DNA-binding domain (DBD), hinge domain, ligand-binding domain (LBD) and C-
terminal domain. The DNA-binding domain is highly conserved and plays an important 
role in the transcriptional regulation of the downstream target. The ligand-binding 
domain is moderately conserved as it requires certain specificity for binding to different 
agonists to initiate the conformational change of the receptors (Wärnmark et al, 2003). 
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There are in total 49 human nuclear receptor genes that have been identified, and these 
nuclear receptors could be classified into 2 types based on its subcellular location. Type I 
nuclear receptors (Type I NR) remain in the cytosol when it is not activated while Type II 
nuclear receptors (Type II NR) reside in the nucleus. According to the mechanism of 
activation, nuclear receptors may be subdivided into the following four classes 
(Mangelsdorf, 1995; Novac and Heinzel, 2004):  
The first class works in the following manner. Ligand binding to type I nuclear receptors 
in the cytosol results in the dissociation of heat shock proteins, homo-dimerization and 
translocation of the nuclear receptors (i.e., active transport) from the cytoplasm into the 
cell nucleus, and binding to specific sequences of DNA known as hormone response 
elements (HRE's) occurs. Type I nuclear receptors bind to HREs which consist of two 
half sites separated by a variable length of DNA and the second half site has a sequence 
inverted from the first (inverted repeat). The nuclear receptor/DNA complex then recruits 
other proteins which transcribe DNA downstream from the HRE into messenger RNA 
and eventually protein translation occur leading to a change in cell function. 
Type II receptors in contrast are retained in the nucleus regardless of the ligand binding 
status and in addition bind as hetero-dimers (usually with RXR) to DNA. In the absence 
of ligand, type II nuclear receptors are often complexed with corepressor proteins. Ligand 
binding to the nuclear receptor causes dissociation of corepressor and recruitment of 
coactivator proteins. Additional proteins including RNA polymerase are then recruited to 
the NR/DNA complex leading to transcription of the gene. 
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Type III nuclear receptors are similar to type I receptors in that both classes bind to DNA 
as homodimers. However, type III nuclear receptors, in contrast to type I, bind to direct 
repeat instead of inverted repeat HREs. 
Type IV nuclear receptors bind either as monomers or dimers, but only a single DNA 
binding domain of the receptor binds to a single half site HRE.  
The nuclear receptors can also be categorized according to their general function. The 
first category represents the nuclear receptors that are related to sterols and hormones, 
which include glucocorticoid, mineralocorticoid, retinoids, vitamin D3, estrogen, 
progesterone and thyroid hormone receptors. These receptors are known to play 
important roles in endocrine functions (Mangelsdorf et al., 1995; Chambon, 1996). 
Members of the second group are referred to as orphan nuclear receptors as these were 
identified without prior knowledge of their ligand and defined gene family ( Giguère et 
al., 1988), via low stringency screening of cDNA libraries and polymerase chain reaction 
screens with degenerate primers (Blumberg and Evans, 1998) and more recently by 
genome sequence analysis (Robinson-Rechavi and Laudet, 2003). These nuclear 
receptors include the arylhydrocarbon receptor (AhR), pregnane X receptor (PXR), 
constitutive androstane receptor (CAR), retinoid X receptor (RXR), liver X receptor 
(LXR) and farnesoid X receptor (FXR). 
Besides classification of mechanism, the nuclear receptors could also be categorized by 
their homology (Appendix A).  
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1.3.1 Glucocorticoid receptor (GR) 
Glucocorticoid receptor belongs to the group C estrogen receptor-like subfamily 
(NR3C1), and cortisol is its natural ligand in human. GR is expressed in almost all tissues 
although tissue-specific and cell cycle-specific regulation of GR levels have been 
reported (Lu et al., 2006). Cortisol is the major glucocorticoid in human exerting a vast 
array of physiological functions via GR. In rodents, the major glucocorticoid is 
corticosterone and not cortisol. Synthetic glucocorticoids used therapeutically such as 
dexamethasone and prednisolone are common exogenous agonists for GR while RU-486 
is a potent GR antagonist. GR plays pivotal roles in physiological functions such as stress 
response, metabolism, immune function, growth, development and reproduction.  
Unliganded GR exists as a complex with heat shock proteins in the cytoplasm. Upon 
binding to cortisol, GR dissociates from the cytoplasmic complex, translocates to the 
nucleus and forms a homodimer followed by binding specifically to its target DNA 
sequence, termed glucocorticoid-response elements (GREs) via the DBD. Classic GREs 
consist of two hexameric (i.e. AGAACA) inverted repeat half-sites separated by a 3-bp 
spacer.  
 
1.3.2 Aryl hydrocarbon receptors (AhR) 
The aryl hydrocarbon receptor (AhR) is a cytosolic ligand–activated transcription factor 
that plays important roles in xenobiotics biotransformation. The receptor binds to co-
chaperones before ligand activation. The first ligands to be discovered were synthetic 
compounds which are members of the halogenated aromatic hydrocarbons (dibenzo-
dioxins, dibenzofurans and biphenyls) and polycyclic aromatic hydrocarbons (3-
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methylcholanthrene, benzo(a)pyrene, benzanthracenes and benzoflavones) (Denison et al., 
2002; Denison and Nagy, 2003). Naturally occurring compounds that have been 
identified include derivatives of tryptophan such as indigo and indirubin (Adachi et al., 
2001), tetrapyroles such as bilirubin (Sinal and Bend, 1997), the arachidonic acid 
metabolites lipoxin A4 and prostaglandin G (Seidel et al., 2001), modified low-density 
lipoprotein (McMillan and Bradfield, 2007) and several dietary carotinoids (Denison and 
Nagy, 2003). AhR belongs to the PAS (Per-ARNT-Sim) family of transcription factors 
which controls the expression of many phase I enzymes such as CYP1A1 and CYP1B1 
(Harrigan et al., 2004) as well as several phase II metabolizing enzymes such as 
glutathione-S-transferases. To date, AhR is still a member of the orphan nuclear receptor 
family. No physiological endogenous ligand of AhR has been identified (Vrzal et al., 
2004). However, its existence is indirectly supported by observations demonstrating 
AhR-dependent responses in the absence of exogenous ligands (Denison et al., 2002; 
Vrzal et al., 2004). Hence AhR plays important physiological roles. AhR is also 
implicated as a mediator of chemical carcinogenesis and teratogenesis via the adverse 
effects of metabolic activation of benzo[a]pyrene and 2, 3, 7, 8-tetrachlorodibenzo-p-
dioxin (TCDD) respectively (Mimura and Fujii-Kuriyama, 2003; Nebert et al., 2004; 
Vrzal et al., 2004). 
 
Upon ligand binding, AhR dissociates from the chaperon proteins and translocates into 
the nucleus, where it heterodimerizes with aryl hydrocarbon receptor nuclear translocator 
(ARNT). The heterodimer binds to specific DNA region termed dioxin or xenobiotic 
response element (DRE or XRE), which has a core sequence of 5’-TNGCGTG-3’ and 
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thereby activates target genes expression (Mimura & Fujii-Kuriyama, 2003). AhR and 
ARNT can form homodimers but neither one is capable of recognizing DREs (Matsushita 
et al., 1993). 
 
1.3.3 Pregnane X Receptor (PXR) 
Pregnane X receptor, also known as NR1I2, was first characterized to sense the presence 
of foreign toxic substances and in response up regulate the expression of proteins 
involved in the detoxification and clearance of these substance from the body (Kliewer et 
al., 2002). The human PXR together with its homologs in rat, rabbit, pig, monkey and 
dog were identified in 1998. Studies have shown that all PXRs (mouse, human, rat and 
rabbit) are predominantly expressed in the liver and intestine, and to a small extent in the 
kidney and lungs (Wang and LeCluyse, 2003). PXR is found exclusively in the nucleus 
and a direct correlation between ligand binding and receptor activation, without the need 
of nuclear translocation has been demonstrated (Handschin and Meyer, 2003). The well 
known exogenous agonists of PXR include pharmaceutical drugs such as RU486 and 
rifampicin; and synthetic steroids such PCN (Willson and Kliewer, 2002). Natural 
endogenous ligands of PXR include bile acids such as lithocholic acid; and pregnanes. 
PXR must be activated by cognate ligands and heterodimerize with RXR before it can 
bind to DNA. Although PXR is commonly associated with the regulation of CYP3A 
genes, it is also able to regulate other gene encoding drug metabolism enzymes and 
pumps. Studies have shown that SULT1E1 was up-regulated through PXR in male mice 
and SULT2A1 and SULT2A2 were induced in female mice (Alnouti and Klaassen, 2008). 
The up-regulation of these proteins enhances uptake of xenobiotics into the liver to be 
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acted upon by phase I (CYPs) and phase II (GST, SULTs) drug metabolizing enzymes. 
These transporters then move the metabolized and conjugated xenobiotics into the body’s 
excretory pathways via the kidney or the bile (Tien and Negishi, 2006). This suggested 
that PXR serves as a master regulator of hepatic drug disposition.   
 
1.3.4 Retinoid X receptor (RXR) 
RXRs are encoded by three distinct human genes, namely the RXRα, RXRβ and RXRγ 
(Mangelsdorf et al., 1990; Mangelsdorf et al., 1992). RXRα (NR2B1) is predominantly 
expressed in the liver, kidney, epidermis and intestine. Expression of RXRβ is widely 
distributed in almost every tissue while RXRγ expression is mostly restricted to muscle 
and certain parts of the brain as well as the pituitary (Mangelsdorf et al., 1992; Dolle et 
al., 1994). 9-cis retinoic acid (9cisRA) was found to be a high affinity ligand for all three 
RXRs (Allenby et al., 1993). Although the biosynthesis and the presence of 9cisRA have 
been reported in developing embryo, 9cisRA has not been detected in mammalian cells. 
Therefore it cannot be concluded that 9cisRA is the actual natural ligand for RXRs 
(Mertz et al., 1997). Thus, RXRs are still regarded as members of the orphan nuclear 
receptors. 
 
All three RXR subtypes are common heterodimerization partners for members of the 
subfamily 1 nuclear receptors, including RAR, PXR, CAR, PPAR and etc. Both in vitro 
and in vivo studies have showed that all these nuclear receptors require RXR as a 
heterodimerization partner for their function and in most cases, the RXR partner does not 
exhibit a marked preference for any one of the three RXR subtypes (Germain et al., 
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2006). RXRs can also form homodimers in vitro however the existence and the functional 
role of RXR-RXR homodimers remains unclear. 
 
1.3.5 Retinoic acid receptor (RAR) 
RARs are members of the nuclear receptor 1B subfamily (NR1B) that can be activated by 
all-trans-retinoid acid (ATRA) and 9-cis retinoid acid. These receptors mediate the 
pleiotropic effects of retinoids regulating a wide variety of essential biological processes 
such as vertebrate embroyonic morphogenesis, organogenesis, cell growth arrest, 
differentiation, apoptosis, homeostasis and their disorders (Sporn et al., 1976; Chambon, 
2005). There are three RAR subtypes originating from three distinct genes: RARα 
(NR1B1), RARβ (NR1B2) and RARγ (NR1B3) (Giguere et al., 1987; Petkovich et al., 
1987). RARα is present in most tissues while both RARβ and RARγ expressions are 
more selective (Dolle et al., 1990), which suggests distinctive functions among the 
different subtypes. Unlike classical steroid hormone receptors, RARs function as 
heterodimers with any of these three retinoid X receptors (RXRα, RXRβ and RXRγ). 
Aberrant retinoid signaling mechanisms have been linked to cancer and 
hyperproliferative diseases. The most direct implication of RAR in human disease is 
found in acute promyelocytic leukemia (APL), characterized by a block to normal 
granulocytic differentiation which, if untreated, results in the lethal accumulation of 
immature promyelocytes. This disease is caused by a reciprocal chromosomal 
translocation between RARα and promyelocyte leukemia protein (PML) leading to 
alterations of both the RARα and PML signaling pathways (de The et al., 1990). 
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Fortunately, retinoid anticancer activity can be demonstrated through the use of 
supraphysiological doses of ATRA in the treatment of APL. 
 
1.3.6 Constitutively activated / androstane receptor (CAR) 
In 1994, the orphan nuclear receptor CAR (NR1I3) was isolated through screening of a 
cDNA library using a probe directed towards a conserved motif in the DNA-binding 
domain (Baes et al., 1994). Unlike other steroid receptors, CAR functions more like RXR 
in that it dimerizes with RXR and is abundantly expressed in the liver and intestine. It is 
reported that RXR-CAR binds to phenobarbital responsive enhancer module (PBREM) to 
induce transcription of CYP2B family of drug-metabolizing enzymes (Baes et al., 1994) 
as well as organic anion transporters such as BSEP, NTCP, OATP2, MRP3 and MDR2 
(Staudinger et al., 2003). In transient and stably transfected HepG2 cells, CAR 
transactivated and triggered high basal activity of target reporter genes regulated by the 
mouse CYP2B10 and the human CYP2B6 PBREM, in the absence of exogenous ligands 
(Sueyoshi et al., 1999). This is consistent with the initial reports describing CAR as a 
constitutively activated receptor. However, unlike most nuclear receptors, the 
transactivation process could be regulated by both agonists and inverse agonists, which 
results in downstream activation or repression of target gene transcription respectively. 
An inverse agonist is an agent which binds to the same receptor binding-site as 
an agonist for a particular receptor and reverses the constitutive activity of the receptor 
(Kenakin, 2004). This phenomenon was observed with two natural compounds: 
androstanol (5α-androstan-3α-ol) and androstenol (5α-androstan-16-en-3α-ol) and thus 
these were identified as endogenous ligands. (Willson and Kliewer, 2002; Wang and 
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LeCluyse, 2003). However, both androstanol and androstenol blocks CAR constitutive 
activity only at high concentrations (micromolar) that are far above those reached in vivo. 
Hence to date, there are no known endogenous agonists that can directly activate CAR in 
physiological pathways. The anti-seizure drugs phenobarbital (PB) and phenytoin are the 
most well-known exogenous activators of CAR. Xenobiotics such as 1, 4-bis[2-(3, 5-
dicholoropyriyloxy)]benzene (TCPOBOP) and 6-(4-chlorophenyl)imidazo[2, 1-b][1, 3] 
thiazole-5-carbaldehyde 0-(3, 4-dichlorobenzyl)oxime (CITCO) have also been shown to 
activate mouse and human CAR respectively (Tzameli et al., 2000; Tien and Negishi, 
2006). 
 
It had been reported that CAR can be indirectly activated by high concentrations of both 
bile acids and bilirubin. Both of these pathways result in detoxification and induced 
clearance of these endogenous toxins. Since normal physiologic concentrations of these 
endobiotics cannot effectively activate the CAR and PXR, these receptors are referred to 
as sensors, most probably to monitor a given physiological status of the organism (for 
example, the amount of fatty acids or cholesterol) to fine tune homeostasis and to protect 
against the consequences of pathologically elevated levels (Gronemeyer et al., 2004; 
Moore et al., 2006).  
 
1.3.7 Estrogen receptor (ER) 
Estrogen receptor is one of earliest nuclear receptors that was discovered and it is named 
after its endogenous ligand, the estrogen hormone (17β-estradiol). There are two isoforms 
of estrogen receptors α and β, which can form homodimer or heterodimer.  Although the 
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two isoforms show overall sequence homology, each isoform has more than one splice 
variant that adds more complexity to the receptor signalling. Both ERs are widely 
expressed in different tissue types, however there are some notable differences in their 
expression patterns: The ERα is found in endometrium, breast cancer cells, ovarian 
stroma cells and in the hypothalamus. The expression of the ERβ protein has been 
documented in kidney, brain, bone, heart, lungs, intestinal mucosa, prostate, and 
endothelial cells (Couse et al., 1997; Babiker et al., 2002; Yaghmaie et al., 2005). 
Besides tissue-specific expression level differentiation, the different isoforms and 
subtypes exhibit differential binding and functional selectivity toward different ligands. 
Estrogen (17β-estradiol) binds equally well to both α and β forms. Estrone and raloxifene 
bind preferentially to the α receptor while estriol and genistein to the β receptor. Subtype 
selective estrogen receptor modulators preferentially bind to either the α- or β-subtype of 
the receptor. Additionally, the different estrogen receptor combinations may respond 
differently to various ligands which may translate into tissue selective agonistic or 
antagonistic effects (Kansra et al., 2005). The ratio of α- to β- subtype concentration has 
been proposed to play a role in certain diseases (Bakas et al., 2007). 
Estrogen receptors could function as conventional nuclear receptors to transactivate gene 
expression of downstream target in nucleus. Studies have shown that estrogen receptors 
can also associate with cell surface membrane proteins to activate other signalling 
pathway such as the GPCR and the MAPK/ERK pathways (Zivadinovic et al., 2005; 
Björnström et al., 2004; Lu et al., 2004; Kato et al., 1995). The expression of estrogen 
receptors has been shown to correlate with breast cancer (Clemons et al., 2002; Fabian 
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and Kimler, 2005;  Harris et al., 2003), obesity (Ohlsson et al., 2000) and aging 
(Yaghmaie et al., 2005).  
 
1.3.8 Peroxisome proliferator-activated receptor (PPAR) 
PPARs were originally identified in Xenopus frogs as receptors that induce the 
proliferation of peroxisomes in cells. The first PPAR (PPARα) was discovered during the 
search of a molecular target for a group of agents then referred to as peroxisome 
proliferators, as they increased peroxisomal numbers in rodent liver tissue, apart from 
improving insulin sensitivity (Berger and Moller, 2002). Three types of PPARs have been 
identified: alpha, gamma, and delta (beta) to date. PPARs play a versatile role in biology, 
the agents which activate them were in turn termed PPAR ligands. The best-known 
PPAR ligands are the thiazolidinediones. All PPARs heterodimerize with the retinoid X 
receptor (RXR) (Miyata et al., 1994) and bind to specific regions on the DNA of target 
genes (Wahli et al., 1995). These DNA sequences are termed PPREs (peroxisome 
proliferator hormone response elements). The DNA consensus sequence is 
AGGTCAXAGGTCA, with X being a random nucleotide. The function of PPARs is 
modified by the precise shape of their ligand-binding domain induced by ligand binding 
and by a number of coactivator and corepressor proteins, the presence of which can 
stimulate or inhibit receptor function, respectively (Wahli et al, 1995). Endogenous 
ligands for the PPARs include free fatty acids and eicosanoids. PPARγ is activated by 




1.4 Nuclear receptors and drug metabolism 
It is not surprising that the drug metabolizing enzymes were well studied to examine the 
importance of drug effects and toxicity. For example, cytochrome P450 CYP2D6 
deficiency could change the response towards drugs such as β-blockers and opioids 
(Johansson et al., 1991; Masimirembwa et al., 1996). Thus, the factors that could cause 
changes in expression of drug metabolism enzymes were intensively studied. In the past 
decades, important new insights have been made relating to the regulatory mechanisms 
governing the expression of drug-metabolizing enzymes and transporters by ligand-
activated nuclear receptors. Specifically, there is strong evidence to demonstrate that 
PCR, CAR, AhR, GR and other receptors form a battery of nuclear receptors that regulate 
the expression of many important drug-metabolizing enzyme and transporters (Urquhart 
et al., 2007).   
CYP3A4 is the most abundant cytochrom P450 and has been found to metabolize more 
than 50% of pharmaceuticals that are currently in use (Wrighton et al., 1996). Its 
expression is regulated by a number of nuclear receptors including PXR (Lehmann et al., 
1998), CAR (Sueyoshi et al., 1999), GR (Pascussi et al., 2000), hepatocyte nuclear factor 
4α (HNF4α) (Tirona et al., 2003), farnesoid X receptor (FXR) (Gnerre et al., 2004), and 
the vitamin D receptor (VDR) (Thummel et al., 2001). Besides CYP3A4, other 
cytochrome P450 enzymes were also shown to be affected by nuclear receptors. CAR 
could up-regulate the expression of CYP2C9 (Gerbal-Chaloin et al, 2001), CYP2C19 
(Chen et al., 2003B) and CYP2B6 (Sueyoshi et al., 1999). GR were shown to up-regulate 
CYP2C9 (Pascussi et al., 2003) and CYP2C19 (Chen et al., 2003B).     
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Besides phase I enzymes, nuclear receptors were shown to regulate the expression of 
phase II enzymes. UDP-gluronosyltransferases (UGTs) are a group of enzymes that 
catalyze the conjugation of glucuronic acid with xenobiotics to enhance their 
hydrophilicity. The UGT1A1 isoform could be up-regulated through PXR (Gardner-
Stephen et al., 2004; Chen et al., 2003A), CAR (Sugatani et al., 2001), and AhR (Yeuh et 
al., 2003). The tissue specific expression of this UGT1A1 was shown to be related to 
specific PXR variants (Urquhart et al., 2007). Glutathione S-transferases (GSTs) are a 
family of phase II enzymes that catalyze the conjugation of glutathione to electrophilic 
xenobiotics and metabolites. Falkner et al. have shown that GST expression in transgenic 
mice is PXR-mediated (Falkner et al., 2001).  
Nuclear receptors were also shown to affect the expression of membrane transporters 
including MDR1 (Geick et al., 2001, Burk et al., 2005), MRP2 (Kast et al., 2002), MRP4 
(Assem et al., 2004), BSEP (Ananthanarayanan et al., 2001), BCRP (Szatmari et al., 











1.5 Nuclear receptors and SULT expression 
Historically, SULT enzymes have not been classified as ‘xenobiotic-responsive’ enzymes, 
unlike cytochrome P450 and UDP-glucuronosyltransferase enzymes. However, studies in 
rodents had showed that SULT isoforms are responsive to xenobiotics including 
phenobarbital, steroidal chemicals and glucocorticoid hormones (Liu and Klaassen, 1996; 
Runge-Morris et al., 1996; Runge-Morris et al., 1998). Studies in cultured rat, murine 
and human hepatocytes, and bovine bronchial epithelial cells have also shown that certain 
SULT genes are responsive to glucocorticoids such as dexamethasone (Dex) and 
hydrocortisone (Beckmann et al., 1994; Duanmu et al., 2002; Runge-Morris, 1998; Wu et 
al., 2001). A glucocorticoid regulatory element had been identified on the rat SULT1A1 
gene (Duanmu et al., 2001; Fang et al., 2003). To date, much of the work had been done 
with rodent SULTs. For human SULT genes, the transcriptional regulation of SULT2A1 
is currently the best characterized but less is known about the other SULTs (Duanmu et 
al., 2002; Echchgadda et al., 2004; Huang et al., 2006; Saner et al., 2005; Seely et al., 
2005; Song et al., 2006). 
Cytosolic SULTs were discovered to sulfate glucocorticoid in late 1970s in rats. PXR 
appears to increase SULT2A1 expression (Sonada et al., 2002). Similarly, VDR 
transcriptionally regulates SULT2A1 in rat, mouse and human (Echchgadda et al., 2004).  
Studies in cultured rat, murine and human hepatocytes, and bovine bronchial epithelial 
cells have also shown that certain SULT genes are responsive to glucocorticoids such as 
dexamethasone (Dex) and hydrocortisone, ligands to GR (Beckmann et al., 1994; 
Duanmu et al., 2002; Runge-Morris, 1998; Wu et al., 2001). A glucocorticoid regulatory 
element had been identified on the rat SULT1A1 gene (Duanmu et al., 2001; Fang et al., 
 21 
2003). Wu et al. previously reported that dexamethasone (Dex) induced SULT1B1 
expression in male but not female rats (Wu et al, 2001).  
Given the above evidence of induction of SULTs, in this study, we examined the effects 
of a whole range of nuclear receptor inducers on human SULT1A3 promoter activities as 
this has not been well examined.   
 
1.6 Significance, aims and study approach 
Human SULT1A3 is an important phase II enzyme responsible for first-pass metabolism 
of orally ingested xenobiotics and also for metabolism of endogenous catecholamines. In 
certain instances, the byproducts of sulfation may be carcinogenic. This enzyme is highly 
expressed in the intestine and fetal liver but modestly in adult liver. Given this, it is thus 
important to understand the transcriptional regulation system of hSULT1A3. Hence, this 
study set out to characterize the 3015bp long hSULT1A3 promoter with the objective of 
unearthing the mode of hSULT1A3 transcriptional regulation. Special focus is set on 
nuclear receptor mediated pathways as these have been shown to tremendously influence 
the expression of drug metabolism enzymes. In recent times, these have also been shown 
to influence the transcription of Phase II genes including some human and rodent UDTs 
and SULTs. Besides, there were some preliminary studies in our lab showing that the 
SULT1A3 enzyme activity was induced in HepG2 cells after treatment with 
glucocorticoids. Through this study, we have elucidated a possible mechanism to explain 
this phenomenon. 
The approach employed is summarised in Figure 1.2. The preliminary step is to identify 
putative nuclear receptor response elements within the 3015bp hSULT1A3 promoter by 
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software analysis. Using these predicted elements as reference, deletion and loss-of-
activity approach were employed to verify the functionality of the elements. Truncated 
promoter constructs were designed systematically to exclude putative elements so that 
their potential contributions towards regulation of promoter activity could be elucidated. 
Next, transient transfection studies were performed by co-transfecting appropriate cell 
lines (HepG2 or Huh7 or MCF7) with the promoter-pGL3 plasmid and the pcDNA6-lacZ 
plasmid as internal transfection control. 
Nuclear receptors activators were first screened to narrow down the possible activated 
nuclear receptors involved. Dose response studies were then carried out to determine the 
suitable activator concentration for induction of hSULT1A3 promoter activity and to 
observe if the modulation was dose-dependent. Truncated studies were then performed 
using relevant constructs and over-expression studies will further determine the 
dependency of hSULT1A3 promoter on various activated nuclear receptors. Site-directed 
mutagenesis studies were also done to further confirm the functionality of the nuclear 
receptor binding sites. 
For each transient transfection performed, the luciferase activity of the cell lysates are 
normalised to the β-galactosidase activity to obtain the relative luciferase activity. This 
relative activity is then further normalised with the respective negative control in 
different sets of experiment and expressed as fold induction. The normalized value is a 
surrogate measure of the hSULT1A3 promoter activity. 
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Figure 1.2 Flowchart of study approach to characterize hSULT1A3 promoter 
Software analysis was first performed to predict putative nuclear response elements 
present in hSULT1A3 promoter. Based on these predictions, truncated hSULT1A3 
promoter constructs were generated and cloned into pGL3 luciferase reporter plasmid. 
Commercial nuclear receptor constructs were also cloned into the pcDNA6a plasmid. 
Presence of nuclear receptors in various cell lines was detected by RT-PCR to determine 
the choice of cell line to screen for various nuclear activators. MTS assay was performed 
on HepG2, Huh7 and MCF7 cell lines for a range of drugs to determine the 
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Determination of Fold Induction 
Luciferase activity was normalized to β-galactosidase activity to obtain RLUs. RLUs of treated 
samples were compared to appropriate negative control to obtain fold induction. 
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2. Material and Methods 
2.1 Chemicals 
Dimethyl Sulfoxide (DMSO), dexamethasone (Dex), prednisolone (Pred), β-
Napthaflavone (BNF), 3-methylcholanthrene (3-MC), pregnenolone-16α-carbonitrile 
(PCN), clotrimazole, rifampcin, mifepristone (RU486), 2-acetylamino fluorene (2-AAF), 
phenobarbital (PB),  1, 4-bis[2-(3, 5-dicholoropyriyloxy)]benzene (TCPOBOP), diallyl 
sulfide, clofibrate, all-trans retinoic acid, 9-cis retinoic acid, 13-cis retinoic acid, estradiol, 
2-methoxy-estradiol (2-ME), 17α-estradiol, penicillin-streptomycin and Dulbecco’s 
modified Eagle medium (DMEM) were purchased from Sigma-Aldrich (St. Louis, USA). 
Fetal bovine serum, Opti-MEM I reduced-serum medium, lipofectamine, trypsin, MEM 
non-essential amino acid and MEM sodium pyruvate solution were purchased from 
Invitrogen Life Science Technologies (Carlsbad, California, USA). Plasmid MidiKit, 
RNeasy MiniKit and QIAshredder were obtained from QIAGEN (Hilden, Germany). The 
Access reverse transcription-PCR system, pGL3 vector, luciferase assay kit, pGEM-T 
vector system I and β -galactosidase enzyme assay system were from Promega (Madison, 
WI, USA). Primers were purchased from Proligo (Boulder, CO, USA). 
 
2.2 Cell Lines and Cell Culture 
HepG2 (Homo sapien hepatocellular carcinoma, Cat # HB8065) cell line and MCF7 cell 
lines were purchased from America Type Culture Collection (ATCC, Manassas, USA) 
while Huh7 (hepatocellular carcinoma) cell line was acquired from RIKEN Bioresource 
Center (Japan). All cell lines were cultured in complete Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 10% (v/v) fetal bovine serum, 100µg/ml 
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streptomycin, 100 units/ml penicillin, 2 mM glutamine, 1mM sodium pyruvate and 
0.1mM non-essential amino acids (NEAA). The cells were grown at 37°C, supplied with 
5% CO2 and 95% air. The HepG2 and HuH7 cell lines were selected as SULT1A3 is 
expressed in these two hepatocellular carcinoma lines and in addition, both lines express 
the relevant nuclear receptors of interest. The MCF7 cells were used as these cells 
express the estrogen receptors and allow for the study of the effects of estrogen..  
 
2.3 Prediction of Putative Nuclear Receptor Response Element 
Web-based MatInspector software (Genomatix, Munich, Germany) assessed at 
http://www.genomatix.de/matinspector.html was used to predict putative nuclear receptor 
response elements present in 3kb hSULT1A3 promoter. The search algorithms were 
described in Quandt et al, 1995 and the selected library used was matrix family library 
version 5.0, ‘all vertebrates.lib’. 
 
2.4 Cloning of Plasmid constructs 
A 3015bp fragment corresponding to the 3-kb region upstream of the SULT1A3 
transcription start site was cloned into the pGL3 reporter vector to generate the pGL3-A 
construct (3015bp construct). This was achieved by PCR amplification using genomic 
DNA extracted from HepG2 cells as template with 1A3/NheI/F (5’-
GTAGCTAGCGCACTATCAGAGGGCAGCACTTATCAC-3’) and 
1A3/XhoI/R (5’-TATCTCGAGTGTGGGAGGGATCTAAAG-3’) as primers. PCR 
leading to the amplification of SULT1A3 promoter was carried with the DyNAzyme 
EXT DNA polymerase kit (Finnzymes, Espoo, Finland). This promoter region spans 
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from -3011 to +4 (+1 denotes the transcription start site on exon III as previously 
described by Aksoy & Weinshilboum, 1995).  
 
The SULT1A3 truncated promoter constructs were subsequently generated by PCR using 
the previously obtained pGL3-A as template together with other primers shown in Table 
2.1 respectively as the forward primer, and 1A3/XhoI/R (5’-
TATCTCGAGTGTGGGAGGGATCTAAAG-3’) as the reverse primer. The resultant 
PCR fragments were first cloned into pGEM-T vector and then subcloned into pGL3.  
Table 2.1 Primers used for cloning 












































































Besides pGL3-A, pGL3-B (1235bp-SULT1A3), pGL3-C (1196bp-SULT1A3), pGL3-E 
(2069bp-SULT1A3) constructs were selected to be used in the further experiments. 
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In addition, a construct with a mutated GRE, pGL3-D was generated by site-directed 
mutagenesis using pGL3-B (1235bp-SULT1A3) as template with GRE/M (5’-
TAGGGCAATGGGACTACAGCATCCTTGTCCTTTCTTATT-3’) and GRE/M/AS 
(5’-AATGAAGAAAGGACAAGGATGCTGTAGTCCCATTGCCCTA-3’) as mutation 
primers following the protocol of the Stratagene QuikChange Site-Directed Mutagenesis 
Kit (La Jolla, CA, USA).  
A construct with mutated AhR, pGL3-F was generated by site-directed mutagenesis using 
pGL3-A (3015bp-SULT1A3) as template with ARE/M (5’- 
GCTGGGATTACATGCGCCTGCCACC -3’) and ARE/M/AS (5’- 
GGTGGCAGGCGCATGTAATCCCAGC -3’) as mutation primers following protocol of 
the Stratagene QuikChange Site-Directed Mutagenesis Kit (La Jolla, CA, USA). 
 
The pcDNA6-β-gal plasmid which contains the β-galactosidase ORF was purchased from 
Invitrogen, USA while a clone carrying the glucocorticoid receptor (GR) ORF was 
purchased from Open Biosystems (Huntsville, AL, USA). This was used as the template 
to PCR the GR ORF using GRF (5’-
CGCGGATCCATGGACTCCAAAGAATCATTAAC-3’) as forward primer and GRR 
(5’-GCCGACCTCGAGTCACTTTTGATGAAACAG-3’) as reverse primer. The PCR 
fragment was then cloned into the pcDNA6a expression vector (Invitrogen, USA) to 
generate pcDNA6-GR.  
pcDNA6-AhR and pcDNA6-ARNT expression plasmids were amplified using designed 
primers by previous graduate student Thomas Neo Wee Leong: AhR forward pimer (5’-
TTAAAGCTTCGTCGGCTGGGCACCATGAA-3’), AhR reverse primer (5’-
 28 
GACCTCGAGATTGGGCTTGGAATTACAGG-3’), ARNT forward primer (5’-
TTAAAGCTTCATCTGCGGCCATGGCG-3’) and ARNT reverse primer (5’-
GACCTCGAGTGGTTCTTGGCTAGAGT-3’). The respective amplicons were cloned 
into pGEM-T vector according to the instructions of suppliers. The ORF of each nuclear 
receptor was extracted using HindIII and XhoI restriction digest, purified and cloned into 
pcDNA6A expression vector. 
The sequences of pcDNA6-GR, pcDNA6-AhR, pcDNA6-ARNT and the four pGL3 
promoter constructs were verified using the BigDye terminator V3.1 cycle sequencing kit 
(Applied Biosystems Inc). 
 
2.5 Isolation of Total RNA and Reverse Transcription-PCR (RT-PCR) 
Total RNA was extracted from HepG2, Huh7 and MCF7 (~1x106 cells) using RNeasy 
Mini Kit (Qiagen, Hilden, Germany). The list of primers used for RT-PCR detection of 
various nuclear receptors is listed in Table 4. One step RT-PCR was performed using the 
Access RT-PCR kit (Promega, Madison, WI, U.S.A). Reverse transcription was carried 
out following the manufacturer’s protocol. The RT-PCR primers are shown in Table 2.2. 
Table 2.2   List of primers used for RT-PCR 
The annealing temperatures of respective primer pairs and the expected fragment size are 
indicated. 
Target 
Gene Primer Sequence 
Annealin








































































































































2.6 Detection of Digested plasmid, PCR or RT-PCR products 
All DNA products were detected using agarose gel electrophoresis. The gel was 
constituted in Tris-acetate-EDTA (TAE) buffer (40mM Tris-acetate, 1mM EDTA) and 
ethidium bromide (Promega, Madison, WI) was added at concentration of 0.5µg/ml. 1kb 
and 100bp ladder were run along with 10µl of samples. Gels were exposed to UV light 
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and excited bands were visualised and captured by G:BOX Chemi XT16 
chemiluminescence image analyzer (SynGene, Fredrick, U.S.A) using the SynGene, 
GeneSnap program (v 6.0.7.03). 
2.7 MTS Assay 
Varying dosage of different drugs were applied to HepG2, Huh7 and MCF7 cell lines and 
the viability of cells were determined using the MTS assay kit (CellTiter 96® Aqueous 
One Solution Cell Proliferation assay, Promega, Madison, WI, U.S.A). 3x103 HepG2, 
Huh7 or MCF7 cells were seeded into each well of 96 well plates. The cells were treated 
with Dex, Pred, 3-MC, BNF, PB, TCPOBOP, PCN, rifampicin, clotrimazole, RU486, all 
trans-retinoic acid (All-trans RA), 9-cis retinoic acid (9-cisRA) 13-cis retinoic acid, 
estradiol, 2-AAF, diallyl sulfide, clofibrate, 2-methoxy-estradiol (2-ME), 17α-estradiol at 
concentrations ranging from 10µM to 1nM for 48 hrs, with fresh drugs replaced every 24 
hrs. All drugs were dissolved in 0.02% DMSO and constituted in DMEM. After 48 hrs of 
treatment, 10µl of MTS tetrazolium reagent was added to each well and incubated at 
37°C for an hour. The plate was read by the SpectraMax 190 platereader (Molecular 
Devices) using the SoftMax Pro (Life Science Edition, v4.3) at 490nm. The cell viability 
was expressed as the absorbance at 490nm of treated cells to that of untreated in 
percentage. The mean percentage cell viability of three independently treated samples 
was then calculated. 
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2.8 Transient Transfection 
All three cell lines (HepG2, MCF-7 and Huh7) were seeded into six-well plates 24 h 
before transfection. 5 × 105 HepG2 cells and MCF-7 cells or 3× 105 Huh7 cells were 
seeded into each well and the plates were incubated for 24 h at 37 ºC in a 5% CO2 
incubator before transfection. For each well, 1 µg of promoter-pGL3 reporter plasmid 
was co-transfected with 0.2 µg of pcDNA6-β-gal expression plasmid. 0.4 µg of pcDNA6a, 
pcDNA6-GR, pcDNA6-AhR or pcDNA6-ARNT were used in over-expression study. 
The plasmids were dissolved in 100 µl of Opti-MEM I reduced-serum medium and 
mixed with Lipofectamine reagent with ratio of 5 µl/ µg DNA transfected, which was 
pre-diluted in 100 µl Opti-MEM I medium. The resultant solution was then allowed to 
incubate at 24 oC for 45 min to allow the DNA-liposome complexes to form. During the 
incubation, the cells were washed with 0.6 ml of Opti-MEM I, following which, 0.8 ml of 
Opti-MEM I medium was added to each well. After 45 min of incubation, 200 µl of the 
DNA-liposome solution was added to each well. The cells were then incubated at 37 oC 
for 5 h in an atmosphere of 95% air and 5% CO2. Following the 5 h incubation, 2 ml of 
DMEM was added to each well and the cells were incubated overnight at 37 oC. The cells 
were then treated for 48 h with various drugs or 0.02 % DMSO. Treatment media were 
changed every 24 h. The concentrations of the drug used ranged from 10-9M to 10-3M. 
After 48 h of treatment, the medium was removed and the cells were washed with PBS. 
This was followed by the addition of 150 µl of freshly prepared reporter lysis buffer 
(RLB) to each well. Cell scrapers were used to detach the cells from the bottom of the 




2.9 Assay of Reporter Gene Expression  
The cell lysates in RLB were thawed quickly and centrifuged at 16,000 × g for 20 min at 
4 ºC to pellet cell debris. Once the spin was completed, the tubes were placed on ice. The 
luciferase and β-galactosidase enzyme assay system (Promega, Madison, WI, U.S.A.) 
were used to determine the luciferase activity and β-galactosidase activity of the cell 
lysates respectively. The assays were carried out according to the manufacturer’s 
recommendations with slight modifications. 
 
For the luciferase assay, 15µl of RLB was pipetted into each well. This was done for 6 
wells of the first row of a white 96-well plate that is suitable for luminometry reading. 5 
µl of cell lysate was then added into each well. 100 µl luciferase assay reagent was then 
added in rapid succession to all wells in the row. The luminescence of each well was 
taken for a 2.5 s period using the Lmax Luminometer (Molecular Devices, Sunnyvale, 
CA, USA). 
 
For the β-galactosidase assay, 50 µl of cell lysate was added to each well in a 96-well 
plate. A series of standards were also included. Thereafter, 50 µl of 2× assay reagent was 
added in rapid succession to all wells. The plates were gently tapped to mix the contents 
and incubated at 37 ºC for 60 mins. 150 µl of 1M sodium carbonate solution was then 
added to each well to stop the reaction. The plates were gently tapped again to mix and 
absorbance at 420 nm was determined. 
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2.10 Statistical Analysis 
All the statistical analysis was performed using either one-way Anova or independent T-



















3.1 Prediction of Putative Nuclear Receptor Response Elements 
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After cloning of SULT1A3 promoter into the pGL3 vector, the promoter sequence was 
first analyzed for putative nuclear receptor response elements using the search algorithm 
based on the configurations of the vertebrate Matrix Family Library Version 5.0 
(February 2005) with minimal 0.75 score point for core sequence similarity and using the 
optimized matrix similarity option provided by the MatInspector program. The matrix 
similarity is optimized such that only a minimum number of matches will be found in 
non-regulatory test sequences and this minimizes false positive matches. The putative 
nuclear receptor binding sites were pulled out and its schematic diagram was shown in 
Figure 3.1. The exact sequence, location and strand of 2 AhR/ARNT, 1 GRE, 2 
PXR/CAR, 1 RAR and 3 ER putative response elements from the search results were 
shown in Table 3.1.   
Based on these putative nuclear receptors sites, a series of truncated hSULT1A3 
promoter constructs were generated as described previously. These truncated promoter 
constructs were systematically generated to exclude certain putative nuclear receptor 
response elements in order to examine their possible transcriptional contributions towards 



























Figure 3.1: Prediction of Putative Nuclear Receptor Response Elements 
(A) Schematic representation of the 5’-region of SULT1A3, the promoter constructs 
and the major putative nuclear receptors response elements. The transcription 
start site (denoted as +1 on exon III was described previously by Aksoy and 
Weinshilboum, 1995), the 5’UTR (exon III) and exon IV are shown. 




Table 3.1 Putative response elements for major nuclear receptors 
The core sequences of all the receptors are shown in capital letter and the basepairs 
marked red represent region that exhibit high conservation. Sense and antisense DNA 





Position Strand Sequence 
AhR/ARNT -2795 to -2773 (-) agcaGGTCactgaatgtccccagggcaag 















site, full length cloning 
region is between -3011 
to +4 






ER -2138 to -2106 (-) actcaccAAGGgcattggc 
ARNT/AhR 
heterodimer -1550 to -1528 (+) gaagctgttcACGTgctagggccag 
RXR/PPAR -1504 to -1484 (-) ggcaagtaggggaaAGCTgaggc 
RXR/PPAR -1432 to -1412 (+) tgcaaataggacAAAGaccaa 
GRE -1211 to -1193 (+) tgggactacagtGTCCttg 
ER -1205 to -1183 (-) aaaggacAAGGacactgta 




-248 to -238 (-) tgagtggaggggaaAGGTgggat 
 
 
3.2 Basal Activity of promoter constructs 
Basal transcriptional activities of truncated promoter constructs are checked to ensure the 
presence of active functional elements. In this particular experimental setup, the cells 
were cultured in DMEM without any drug treatment. The relative luciferase activity of 
the truncated constructs were normalised with that of the promoterless pGL3 plasmid 
(negative control). Basal transcriptional activity was observed in all truncated constructs 


































Figure 3.2: Basal Activity of Promoter Construct in HepG2 cells  
Transfected HepG2 cells were grown in DMEM for 48hours and harvested. The 
promoter-less pGL3 vector or the promoter-pGL3 reporter plasmids were each co-
transfected into HepG2 cells with pcDNA6-β-gal expression plasmid as the transfection 
control. Cell lysates were assayed for luciferase activity, which was normalized to β-
galactosidase activity. The normalized activity of the promoter-less pGL3 vector was 
then assigned as one and the activities of all other constructs were expressed in terms of 
corrected luciferase activity. Error bars represent the standard deviation of three 
independent experiments. * denotes significant difference (p < 0.05) between the 
activities of the promoter constructs and the promoter-less pGL3. 
 
 
3.3 Nuclear Receptor Expression Profiles of HepG2, Huh7 and MCF7 cell lines 
In order to use cell lines as in vitro models to study the effects of activated nuclear 
receptors on the regulation of hSULT1A3 gene, the expression levels of various nuclear 
receptors in HepG2, Huh7 and MCF7 were examined using RT-PCR. 
HepG2 was found to express somewhat high levels of AhR, ARNT, RARα, RARγ, GRα 
and GRβ. However, while RXRα was expressed at an intermediate level, both RARβ and 
PXR were only expressed at low levels. No detectable CAR and ER transcripts were 
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found to be expressed in HepG2. In the same experiment, Huh7 was found to express 
rather high levels of AhR, ARNT, RARα, RARβ, RXRα, GRα and GRβ. RARγ was 
found be expressed at an intermediate level while both PXR and CAR were found to be 
expressed at low levels, and no ER was found to be expressed. MCF7 was found to 
express high levels of ER, RARα and GRα, intermediate level of AhR and low levels of 
GRβ and RARγ. For each reverse transcription-PCR reaction, the appropriate negative 
control without reverse transcriptase was included. In such controls, no DNA products 
were detected. Hence, this indicated that there was no detention of genomic DNA for 
these reactions. The results are summarized in Table 3.2. 
Based on the nuclear receptor expression profiles, initial xenobiotics screening of AhR, 
RAR and GR activators were performed firstly in HepG2 cells followed by an additional 
screening in Huh7 cells as both cell lines expressed nuclear receptors. Since both PXR 
and CAR were found to be expressed at low levels only in Huh7 cell line, initial 
screening of PXR and CAR activators were performed only in Huh7 cell line. ER was 
only found to be expressed in MCF7, thus the initial screening of ER activators was 
















Table 3.2 Expression of nuclear receptor transcripts in HepG2, Huh7 and MCF7 
cells  
Total RNA extraction and RT-PCR of the nuclear receptor transcripts were performed. β-
Actin was served as the positive control. RT-PCR products were size fractionated on 1% 
agarous gel and visualized by staining with ethidium bromide. Bands were scored using a 
scale of undetectable (-), low (+), intermediate (++), high (+++), very high levels of 
products (++++) or Not Applicable (N.A.).  
Nuclear Receptor HepG2 Huh7 MCF7 
β-Actin ++++ ++++ ++++ 
AhR ++++ ++++ ++ 
ARNT ++++ ++++ N.A. 
RARα ++++ ++++ +++ 
RARβ + +++ - 
RARγ +++ ++ + 
RXRα ++ +++ N.A. 
PXR + + - 
CAR - + N.A. 
GRα +++ +++ +++ 
GRβ ++++ +++ + 
ER - - +++ 
 
3.4 Cytotoxicity of activators of nuclear receptors to cell lines 
Before the initial screening of nuclear receptor activators (i.e. xenobiotics) on their ability 
to activate hSULT1A3 promoter activity, it was necessary to ensure that the highest 
concentrations of each xenobiotic used did not compromise cell viability significantly. 
The cytotoxicity assay was performed with 0.02% DMSO or various concentrations of 
drugs dissolved in 0.02% DMSO using untreated cells as controls with 100% viability.  
The results of the MTS assay are shown in Table 3.3. All drugs examined did not show 
any significant reduction on HepG2, Huh7 and MCF7 cell viability at 10µM or 1µM, 
including 1000µM of PB. It was also noted that there was no significant reduction of cell 
 40 
viability observed in cells treated with 0.02% DMSO. This indicated that the solvent used 
did not cause any toxicity to cells. In summary, the highest concentration of nuclear 
receptor activators that can be used for subsequent transfection studies was 1000µM for 
PB, 10µM for Dex, Pred or 13-cisRA and 1µM for all other compounds used in the 
screening. 
Table 3.3 Effects of nuclear receptor activators on cell viability 
The cell viability of untreated cells was set as 100%. The cell viability of each treatment 
was expressed as a ratio of the absorbance at 490nm of treated cells to that of untreated 
cells in percentage. Data are expressed as mean percentage cell viability ± S.E.M of three 
independently treated samples (n = 3). * denotes statistically significant difference 















HepG2 - Untreated - 100.00 ± 6.92 
  DMSO 0.02% (v/v) 103.01 ± 4.50 
 AhR β-Napthoflavone (BNF) 1 126.71 ± 14.39 
  3-Methylcholanthrene (3-MC) 1 109.93 ± 9.45 
 PXR Clotrimazole 1 107.49 ± 4.04 
 GR Dexamethasone (Dex) 10 101.52 ± 5.39 
  Prednisolone (Pred) 10 102.06 ± 9.88 
 PPAR Clofibrate 1 95.34          ±  3.85 
Huh7 - Untreated - 100.00 ± 17.88 
  DMSO 0.02% (v/v) 111.37        ±  6.37 
 AhR β-Napthoflavone (BNF) 1 116.20 ± 8.70  
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  3-Methylcholanthrene (3-MC) 1 106.58 ± 8.68 








 RXR 9-cis retinoic acid (9-cisRA) 1 90.53          ±  2.45 
 GR Dexamethasone (Dex) 10 103.48 ± 2.19 
  Prednisolone (Pred) 10 91.21          ±  1.19 
 PXR Pregnenolone-16α-carbonitrile (PCN) 1 
104.45 ± 
11.75 
  Rifampicin (RIF) 1 83.55 ± 10.02 
  Mifepristone (RU486) 1 89.73          ±  9.65 




96.26          ±  
5.82 
 CAR Phenobarbital (PB) 1000 94.66 ± 10.11  
  Diallyl Sulphide (DAS) 1 88.58 ± 13.69 
  TOCBOP 1 88.34 ± 1.34 
MCF7  Untreated - 100             ±  7.56 
  DMSO 0.02% (v/v) 85.84 ± 13.34 
 ER Estradiol 1 87.45 ± 12.44 
  17α-Estradiol 1 92.11          ±  8.15 






3.5 Effects of Nuclear Receptor Activators on hSULT1A3 Promoter Activity 
The nuclear activators were tested for their ability to activate hSULT1A3 promoter 
activity. The cells were treated with drugs for 48hr and the cells were then lysed and 
assayed for the luciferase activity. The results are summarized in table 3.4. 
Table 3.4 Effects of Nuclear Receptor Activators on hSULT1A3 Promoter Activity 
The table listed all the compounds that have been tested in the screening assay, the 
respective concentration used, the ligand receptors that was involved, the cell type that 
was used for transient transfection and the response. 
Compound Concentration Receptor Cell Type Response 
Dexamethasone 1nM to 10µM GR HepG2 and Huh7 Yes 
Prednisolone 1nM to 10µM GR HepG2 and Huh7 Yes 





AhR HepG2 and Huh7 Yes 
PCN 1nM to 1µM PXR Huh7 No 
Clotrimazole 1nM to 1µM PXR HepG2 and Huh7 No 
Rifampcin 1µM PXR Huh7 No 
Mifepristone 
(RU486) 
1µM PXR Huh7 No 
2-AAF 1µM PXR Huh7 No 
phenobarbital 1mM CAR Huh7 No 
TOCBOP 1µM CAR Huh7 No 
Diallyl sulfide 1µM CAR Huh7 No 
Clofibrate 1µM PPAR HepG2 No 
All-trans Retinoic 
acid 
1µM RAR Huh7 No 
9-cis retinoic acid 1µM RXR Huh7 No 
13-cis retinoic acid 1µM to 10µM RAR Huh7 No 
Estradiol 1µM ER MCF7 No 
2-methoxy-Estradiol 1µM ER MCF7 No 
17α-Estradiol 1µM ER MCF7 No 
 
Only 4 compounds were observed to activate the promoter activity. Dex and Pred are GR 
activators, while β-Napthaflavone (BNF) and 3-methylcholanthrene (3-MC) are AhR 
activators. All the other compounds tested showed neither activation nor suppression on 
the promoter activity. 
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Since the activators were found to be active in both cell lines, HepG2 and Huh7, the cell 
lines with the higher response were chosen to be used in further studies. Thus, the HepG2 
cells were used in GRE studies, and Huh7 cells were used in AhR studies. 
 
3.6 Prediction of putative GRE site 
Based on the results of last section 3.5, we next determined if the putative GRE (see 
section 3.1 for prediction) was the binding site for this activation. A series of SULT1A3 
promoter clones were selected to delineate if this was indeed responsible for the response 
to glucocorticoids (Fig. 3.3). All constructs contained sequences that start at +4 of exon 
III of the SULT1A3 gene that was previously determined to be active (Aksoy and 




                        
Fig.3.3: Schematic representation of the 5’-region of SULT1A3, the promoter 
constructs generated for this study 
 The transcription start site (denoted as +1 on exon III was described previously by 
Aksoy and Weinshilboum, 1995), the 5’UTR (exon III), the glucocorticoid response 
element (GRE) and exon IV are shown. The black portion of exon IV denotes the coding 
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3.7 Effects of glucocorticoids on SULT1A3 promoter 
The effects of the glucocorticoids, Dex and Pred on the SULT1A3 promoter were next 
examined using the longest promoter construct pGL3-A. Induction by Dex was observed 
from concentrations ranging from 10-9M to 10-6M (Fig. 3.4A) while induction by Pred 




















































































Fig. 3.4: Dose-dependent induction of SULT1A3 promoter by (A) dexamethasone 
(Dex) and (B) prednisolone (Pred). The pGL3-A plasmid was co-transfected into HepG2 
cells with pcDNA6-β-gal expression plasmid. Cells were then treated with 0.02% DMSO 
or increasing concentrations of (A) Dex or (B) Pred for 48 h. Cell lysates were assayed 
for luciferase activity, which was normalized to β-galactosidase activity. Induction is 
expressed as the ratio of normalized activity in the presence of Dex (or Pred) to the 
activity in the presence of DMSO. Data shown represent mean induction ± SD of six 
independent experiments. Significant difference between treatment and DMSO control is 
denoted with by * (p < 0.05). 
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3.8 Over-expression of GR in HepG2 cells 
To ascertain the involvement of GR in the transcriptional regulation of SULT1A3, over-
expression studies were conducted to determine the effects of elevated GR concentration 
on the transcriptional activation of SULT1A3 promoter in response to Dex. Over-
expression was achieved by co-transfecting the pcDNA6-GR expression plasmid with the 
pGL3-A and pcDNA6-β-gal plasmids into HepG2 cells. It was observed that over-
expression of GR significantly increased the level of induction of the SULT1A3 promoter 
in response to Dex treatment. A 4-fold increase was observed when the transfected cells 
were treated with 0.1 µM DEX in the absence of GR over-expression. However, a more 


































pcDNA6a       + -      +     - 
pGL3       + +     -     - 
pcDNA6-GR       - +     -     + 
 pGL3-A       - -     +       + 
 
Fig. 3.5. Effect of overexpression of glucocorticoid receptor on the reporter activity 
of the pGL3-A reporter construct  
The plasmids as indicated were co-transfected with pcDNA6-β-gal expression plasmid 
into HepG2 cells. Cells were then treated with  
10-7M Dex for 48 h. Cell lysates were assayed for luciferase activity, which was 
normalized to β-galactosidase activity. The normalized activity of the promoter-less 
pGL3 vector / pcDNA6a was then assigned as one and all other the activities were 
expressed as fold of this (corrected luciferase activity). Data shown represent mean ± SD 






3.9 Identification of the glucocorticoid response element 
Two truncated constructs, pGL3-B and pGL3-C were used to determine whether the 
predicted GRE site, 5’ TGGGACTA CAG TGTCCTTG 3’, at position (-1211 to -1193) 
upstream of the transcription start site was the region that is responsive to glucocorticoids. 
The longer pGL3-B includes the predicted GRE while the shorter construct, pGL3-C is 
39bp shorter and does not include the putative element (Fig. 3.3A). Beside these, the 
pGL3-D mutant construct was also generated. pGL3-D is identical to pGL3-B with the 
exception of mutations at the core GRE sequence resulting in a change from 
GGACTACAGTGTCCT to GGACTACAGCATCCT. The response to Dex was evident 
with the longer pGL3-B construct but was completely abolished with the shorter pGL3-C 
and the mutant pGL3-D constructs (Fig. 3.6). It was also observed that over-expression of 
pcDNA6-GR significantly induces the transcriptional activity of pGL3-B but not pGL3-C 
or pGL3-D in the presence of Dex (Fig. 3.7). This suggests that the GRE is indeed 






























Fig. 3.6: Effect of dexamethasone on the reporter activity of the SULT1A3 
promoter deletion constructs. Each truncated promoter-pGL3 plasmid or the 
promoter-less pGL3 vector was co-transfected into the HepG2 cells with 
pcDNA6-β-galactosidase plasmid. Cells were then treated with 0.02% DMSO 
(white bars) or 10-7M Dex (black bars) for 48 h. Cell lysates were assayed for 
luciferase activity, which was normalized to β-galactosidase activity. The 
normalized activity of the promoter-less pGL3 vector treated with DMSO was 
then assigned as one and the activities of all other constructs are expressed as fold 
of this (corrected luciferase activity). Error bars represent the standard deviation 
of three independent experiments. * denotes significant difference (p < 0.05) 
































Fig. 3.7: Effect of over-expression of glucocorticoid receptor on the reporter activity 
of the truncated and mutant constructs. The plasmids as indicated and the pcDNA6-β-
gal plasmid were co-transfected with pcDNA6-GR (black bars) or with pcDNA6a (white 
bars) into HepG2 cells. Cells were then treated with 10-7M Dex for 48 h. Cell lysates 
were assayed for luciferase activity, which was normalized to β-galactosidase activity. 
The normalized activity of the promoter-less pGL3 vector / pcDNA6a was then assigned 
as one and the activities of all other constructs are expressed as fold of this (corrected 
luciferase activity). Data shown represent mean ± SD of three independent experiments. 
 
3.10 Prediction of putative AhR/ARNT site 
Based on the results of section 3.5, we also proceeded to determine if the putative 
AhR/ARNTs predicted by MatInspector (section 3.1) were the binding sites for this 
activation. A series of SULT1A3 promoter clones were selected to delineate if this was 
indeed responsible for the response to AhR ligands (Fig. 3.8). All constructs contained 
sequences that start at +4 of exon III of the SULT1A3 gene that was previously 




Figure 3.8: Schematic representation of the promoter constructs and the 5’-flanking 
region of SULT1A3 
 The transcription start site (denoted as +1 on exon III was described previously by 
Aksoy and Weinshilboum, 1995), the 5’UTR (exon III), the AhR response element 
(AhRE) and exon IV are shown. The black portion of exon IV denotes the coding 
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-2795 to -2773 
5’GCTGGGATTACACGCGCCTGCCACC3’ 
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3.11 Effects of AhR ligands on SULT1A3 promoter 
The effects of the BNF and 3-MC on the SULT1A3 promoter were next examined using 
the longest promoter construct pGL3-A. Induction by BNF was observed from 
concentrations ranging from 10-9M to 10-7M (Fig. 3.9A) while induction by 3-MC was 
only observed at the concentration ranging from 10-10M and 10-7M (Fig. 3.9B). At the 
same concentration of 10-7M, BNF could induce a nearly 3-fold expression while 3-MC 
only achieved a 2-fold induction. Thus, BNF was chosen to be the inducer for further 













































































Figure 3.9: Concentration-dependent induction of SULT1A3 promoter by (A) β-
napthoflavone (BNF) and (B) 3-methylcholanthrene (3-MC). The pGL3-A plasmid was 
co-transfected into Huh7 cells with pcDNA6-β-gal expression plasmid. Cells were then 
treated with 0.02% DMSO or increasing concentrations of (A) BNF or (B) 3-MC for 48 h. 
Cell lysates were assayed for luciferase activity, which was normalized to β-galactosidase 
activity. Induction is expressed as the ratio of normalized activity in the presence of BNF 
(or 3-MC) to the activity in the presence of DMSO. Data shown represent mean induction 
± SD of six independent experiments. Significant difference between treatment and 
DMSO control is denoted with by * (p < 0.05). 
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3.12 Over-expression of AhR/ARNT in Huh7 cells 
To ascertain the involvement of AhR in the transcriptional regulation of SULT1A3, over-
expression studies were conducted to determine the effects of elevated AhR and ARNT 
concentration on the transcriptional activation of SULT1A3 promoter in response to BNF. 
Over-expression was achieved by co-transfecting the pcDNA6-AhR or/and pcDNA6-
ARNT expression plasmids with the pGL3 or pGL3-A and pcDNA6-β-gal plasmids into 
Huh7 cells. It was observed that over-expression of AhR, ARNT and co-transfection of 
both did not significantly increase the level of induction of the SULT1A3 promoter in 

































pcDNA6a     +      - -      -      -      +      -       -
 
      - 
pcDNA6-ARNT     -      -          +     +      -      -      +      + 
pcDNA6-AhR     -     + -      -     +      -      +       -      + 
 pGL3-A     -      - -      -      -      +      +      +      + 
pGL3    +     +         +     +      -      -       -       - 
 
Figure 3.10: Effect of over-expression of AhR and ARNT on the reporter activity of 
the pGL3-A reporter construct. The plasmids as indicated were co-transfected with 
pcDNA6-β-gal expression plasmid into Huh7 cells. Cells were then treated with  
10-7M DMSO (white bars) and BNF(black bars) for 48 h. Cell lysates were assayed for 
luciferase activity, which was normalized to β-galactosidase activity. The normalized 
activity of the promoter-less pGL3 vector / pcDNA6a was then assigned as one and all 
other the activities were expressed as fold of this (corrected luciferase activity). Data 





3.13 Identification of the AhR/ARNT response element 
Two truncated constructs, pGL3-C and pGL3-E were used to determine whether the two 
predicted AhR/ARNT sites, 5’ AGCAGGTCACTGAATGTCCCCAGGGCAAG 3’, at 
position (-2795 to -2773) or 5’ GAAGCTGTTCACGTGCTAGGGCCAG 3’, at position 
(-1550 to -1528) upstream of the transcription start site were the region that is responsive 
to BNF. The full length pGL3-A includes both AhR/ARNT sites, the longer pGL3-E 
includes only 1AhR/ARNT while the shorter construct, pGL3-C does not include any 
putative element (Fig. 3.8). The response to BNF was evident with the full length pGL3-
A construct but was completely abolished with the shorter pGL3-E and pGL3-C 
constructs (Figure 3.11). This suggested that putative response element present at 
position -2795 to -2773 might be responsible for the induction of SULT 1A3 promoter 
activity by BNF.  
Thus, the pGL3-F mutant construct was generated to mutate the AhR/ARNT site at 
position -2795 to -2773. The pGL3-F is identical to pGL3-A with the exception of 
mutations at the core AhR/ARNT sequence resulting in a change from 
GCTGGGATTACACGCGCCTGCCACC to GCTGGGATTACATGCGCCTGCCACC. 
The response to BNF was evident with the full length pGL3-A construct but was 
completely abolished with the shorter pGL3-E and the mutant pGL3-F constructs (Fig. 
3.12). This suggested that the predicted AhR/ARNT is important for the induction of 



























Figure 3.11: Effect of β-napthoflavone on the reporter activity of the SULT1A3 
promoter constructs. Each truncated promoter-pGL3 plasmid or the promoter-less 
pGL3 vector was co-transfected into the Huh7 cells with pcDNA6-β-galactosidase 
plasmid. Cells were then treated with 0.02% DMSO (white bars) or 10-7M BNF (black 
bars) for 48 h. Cell lysates were assayed for luciferase activity, which was normalized to 
β-galactosidase activity. The normalized activity of the promoter-less pGL3 vector 
treated with DMSO was then assigned as one and the activities of all other constructs are 
expressed as relative luciferase activity. Error bars represent the standard deviation of 
three independent experiments. * denotes significant difference (p < 0.05) between 


































Figure 3.12: Effect of β-napthoflavone on the reporter activity of the SULT1A3 
promoter deletion constructs. Each truncated promoter-pGL3 plasmid or the promoter-
less pGL3 vector was co-transfected into the Huh7 cells with pcDNA6-β-galactosidase 
plasmid. Cells were then treated with 0.02% DMSO (white bars) or 10-7M BNF (black 
bars) for 48 h. Cell lysates were assayed for luciferase activity, which was normalized to 
β-galactosidase activity. The normalized activity of the promoter-less pGL3 vector 
treated with DMSO was then assigned as one and the activities of all other constructs are 
expressed as relative luciferase activity. Error bars represent the standard deviation of 
three independent experiments. * denotes significant difference (p < 0.05) between 




















Multi-drug resistance (MDR) is one of the major problems in clinical medicine we have 
encountered over the past decades. The discovery of the trans-membrane protein super-
family ABC has launched a new milestone in revealing the mechanism underneath 
(Juliano & Ling, 1976). Around the same period, through the study of endogenous 
hormones, a new group of transcription factor and receptor system was discovered, and 
this group was named nuclear receptors. Scientists later discovered the connection that 
nuclear receptors transactivate drug metabolizing enzymes that partially contribute to the 
MDR. Recent in vivo and in vitro studies showed increasing evidences which suggest that 
sulfotransferase, a phase II enzyme, could also be transcriptional regulated by activated 
nuclear receptors in response to xenobiotics exposure. Hence, in this study, we examined 
the effects of some nuclear receptor ligands on induction of SULT1A3, which has not 
been studied for the human SULT1A3 gene. GR and AhR activators were found to 
induce the promoter activity of SULT1A3. Moreover, the over-expression of GR led to 
amplification of this effect. Mutation at the critical base in the binding recognition site for 
either GR or AhR totally abolish the inductive effects by GR or AhR activators.    
 
4.1 Prediction of receptor binding sites 
The prediction of the transcriptional binding sites was carried out using the online 
software MatInspector (Genomatix, Munich, Germany, 
http://www.genomatix.de/matinspector.html). The prediction of the sites was determined 
by the algorithms of the program using consensus sequence pulled out from previous 
known binding site sequences. However, false positives and the false negatives are 
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always present during these bio-computing processes. These two problems could be 
minimized by manually inputting the other possible binding site sequences followed by 
validation through experimental confirmation. Meanwhile, the algorithm and matrix 
library is also updated when new discoveries of binding sites were determined. In the 
beginning of this study, the MatInspector version used was release 7.4 with Family 
Matrix Library version 5.0. Over the years, this program has been updated. The current 
version is release 7.7.3.1 with Family Matrix Library version 8.0 updated in December 
2008 (http://www.genomatix.de/matinspector.html). By comparison of the search results 
between the previous and current version, the putative sites obtained were present in the 
prediction by both versions with slight modifications on region of the binding site and the 
critical binding base of the matrix.  For certain recognition site, the sequence has been 
modified. However, the updates adopted by the new version were not crucial in our study 
because all the putative sites were validated experimentally. 
  
4.2 Induction of SULT1A3 by ligands of GR and AhR  
To date, there had been few studies on the effects of xenobiotics on the expression of 
human SULT1A genes. A recent study by Hempel et al showed that human SULT1A 
genes were not responsive to nuclear receptor mediators such as Dex, rifampicin and 3-
methylcholanthrene (Hempel et al., 2004). However, various other studies did provide 
indications that this may not be the case. Increased sulfate conjugation activity toward a 
SULT1A1 substrate, 7-hydroxycoumarin was observed in HepG2 cells following 
treatment with 3-methylcholanthrene (Dawson et al., 1985). Induction of SULT1A1 
expression by all-trans retinoic acid and plant phenolic acids such as gallic acid had also 
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been reported (Maiti et al., 2005; Yeh et al., 2005). In human hepatocytes, the sulfation of 
p-nitrophenol, which is a substrate for SULT1A1 was increased following treatment with 
rifampicin (Kern et al., 1997). These observations provide indications that SULT1A1 
may indeed be regulated by nuclear receptors. Induction of human SULT1A3 has also 
been reported. Methotrexate and β-naphthoflavone can induce the expression of 
SULT1A3 (Chen et al., 2005; Miyano et al., 2005). Although the mechanisms for the 
induced expressions were not established in these studies, the inductions were probably 
mediated by the constitutive androstane receptor (CAR) and the aryl hydrocarbon 
receptor (AhR). Binding sites for CAR and for AhR were predicted by the MatInspector 
program to be present on the SULT1A3 promoter and methotrexate and β-
naphthoflavone have been shown to mediate induction of genes via CAR and AhR 
respectively (Chen et al., 2007; Yueh et al., 2003). Induction of M-PST (SULT1A3) 
activity by Dex has also been reported (Walle et al., 1993A).  
In a preliminary study the pretreatment of HepG2 cells with Dex or Pred did not have any 
effect on the sulfation of p-nitrophenol, a SULT1A1 substrate. This is congruent with 
previous studies which had shown that the human SULT1A1 gene, unlike the rat 
SULT1A1 (rat aryl sulfotransferase) gene, is not responsive to glucocorticoids (Duanmu 
et al., 2002; Hempel et al., 2004). In contrast, sulfation of the SULT1A3 substrate, 
dopamine, was elevated. This observation together with an earlier report of induction of 
M-PST (SULT1A3) activity toward albuterol (salbutamol) following Dex treatment 
(Walle et al., 1993A) led us to conduct a systematic investigation on the regulation of the 
SULT1A3 gene by glucocorticoids, Dex and Pred. 
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Therefore, in this study, the 5’-flanking region of the SULT1A3 gene was obtained and 
cloned in the promoter-less pGL3 plasmid which encodes the luciferase ORF. The 
longest construct which encodes 3015bp of the 5’-flanking region was responsive to the 
glucocorticoids, Dex and Pred as well as the AhR activators, BNF and 3-MC. The 
increase in luciferase activity was concentration-dependent and maximal response was 
observed at 10-7M Dex, 1µM Pred, 100nM BNF and 100nM 3-MC. Both the SULT1A3 
enzyme activity and promoter construct activity were more responsive to Dex than to 
Pred. This provides evidence that the induction of SULT1A3 may be GR-mediated since 
the induction response corresponds to the affinity of GR for these two ligands. GR has 
been shown to have a higher affinity for Dex than for Pred (Kontula et al., 1981). As for 
AhR activator, the results were consistent with the findings discovered by Yueh et al. that 
the induction of sulfotransferases could be AhR-mediated although as yet the mechanism 
was not clear at this moment (Yueh et al., 2003).  
 
4.3 Regulation of SULT1A3 by glucocorticoids via GR 
Regulation of rat SULT genes by glucocorticoids has been shown to proceed via different 
mechanisms (Runge-Morris & Kocarek, 2005). The first which has been observed for the 
rat SULT1A1 gene involves the binding of GR to the GRE on the SULT1A1 gene 
(Duanmu et al., 2001; Runge-Morris & Kocarek, 2005). In contrast, the regulation of the 
rat SULT2A-40/41 gene by glucocorticoids is independent of the presence of GRE on the 
gene. At physiological concentrations of glucocorticoid (≤ 10-7M Dex), induction of the 
rat SULT2A-40/41 gene is achieved through glucocorticoid-induced expression of liver-
enriched transcription factors such as C/EBPα and C/EBPβ, which in turn activates 
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transcription of the SULT2A gene (Runge-Morris & Kocarek, 2005; Fang et al., 2005). 
In addition, at higher concentrations (> 10-7M Dex), glucocorticoids can activate PXR 
and further induce SULT2A transcription (Runge-Morris & Kocarek, 2005; Runge-
Morris et al., 1999). The inverted repeat-0 nuclear receptor motif (IR0 motif) on the 
SULT2A-40/41 gene has been shown to be necessary for this to occur (Runge-Morris et 
al., 1999).  
 
Although HepG2 cells constitutively express GR, the level is low (Usui et al., 2006). GR 
over-expression in these cells resulted in a more pronounced response to 10-7M Dex. At 
10-7M, the concentration of Dex is not sufficient to active the pregnane X receptor 
(Duanmu et al., 2002; Runge-Morris & Kocarek, 2005; Runge-Morris et al., 1999). This 
together with the lack of response to PXR ligands, indicates that the Dex-GR dimer is 
responsible for the pronounced response. In addition, a consensus binding site for the 
glucocorticoid receptor was identified by the MatInspector program at position -1211 to -
1193. Deletion of this predicted GRE led to a loss of response to Dex. Mutation of the 
GR consensus binding site also resulted in a loss of response. Taken together, the data 
from this study shows that human SULT1A3 gene is inducible by glucocorticoid through 
a GR-mediated mechanism and the glucocorticoid response element that is present on the 
5’-flanking region is necessary for this induction.  
In this study we demonstrated that human SULT1A3 gene is activated by Dex and Pred. 
Given that SULT1A3 and GR are both expressed in many tissues including the 
gastrointestinal tract and bronchial epithelial cells (Chen et al., 2003B; Sheppard, 2002; 
Windmill et al., 1998), the regulation of SULT1A3 by glucocorticoids may have 
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physiological and clinical relevance. It is indeed of interest to note that the 
pharmacokinetics of ingested salbutamol was affected by the GR ligand, budesonide. The 
plasma concentrations of salbutamol were lowered significantly in patients after 
administration of budesonide and this was attributed to the changes in metabolism of 
salbutamol (Naidu et al., 2003). Since salbutamol is metabolized exclusively by 
SULT1A3 to the inactive sulfate conjugate (Walle et al., 1993B), it is likely that 
induction of SULT1A3 activity by the GR ligand, budesonide led to increased 
metabolism and hence lowered plasma levels.  
 
4.4 Regulation of SULT1A3 via AhR 
Regulation of SULTs gene by AhR activators is much less studied compared to GR. In 
addition, the results were often shown to have repressive effects. The repression of 
SULTs have been observed in mice (Alnouti & Klaassen, 2008), primary rat hepatocytes 
(Runge-Morris, 1998) and human liver cytosol (Moon et al., 2006). These findings were 
correlated to the fact that a group of AhR ligands, the flavonoids, is a potent 
detoxification and anticarcinogenic agent that could inhibit sulfation-induced 
carcinogenesis (Glatt, 2000; Moon et al., 2006). Besides, these inhibitions of SULTs by 
flavonoids were not due to AhR-mediated transcription regulation but non-competitive 
binding to the enzymes (Ghazali and Waring, 1999; Harris et al., 2004). In this study, we 
have demonstrated the induction of SULT1A3 promoter activity using BNF and 3-MC, 
which is consistent with the findings done by Miyano et al. 2005. However, the over-
expression of AhR constructs in the cells did not induce additional SULT1A3 promoter 
activity. This could be explained by two possibilities. First, the AhR expression in Huh7 
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cells was high, thus, the amount of the receptors present was adequate to carry out the 
induction. Second, AhR could be repressed by AhR repressor protein (AhRR). This 
AhRR protein binds to AhR to prevent the AhR complex transactivating downstream 
target (Hahn et al., 2008; Mitchell and Elferink, 2008). Interestingly, the expression of 
AhRR could also be induced by AhR complex, creating a negative feedback loop for 
repressive regulation (Hahn et al., 2008). Therefore, over-expression of AhR could lead 
to negative feedback abolishing the effect of over-expression. The mutation of putative 
AhR binding site between positions -2795 to -2773 did abolish the induction of the 
SULT1A3 promoter completely, thus providing strong evidence that the putative AhR 
binding site is critical for the induction by AhR. However, the mechanism of this AhR-
mediated induction is still not fully elucidated and one means of confirming this will be 
via experiments which show the direct binding of AhR to the binding site by 
Electrophoretic Mobility Shift Assay (EMSA). 
 
4.5 Effects of other nuclear receptor ligands on SULT1A3 
There were no obvious inductive effects observed by other inducers. However, this could 
be simply a false negative result. As in vivo DNA is packed as extremely condensed 
structures, the transcription factor binding sites could be a few kb away from 
transcription starting site. Thus, 3015bp of the promoter might not contain the binding 
sites needed to activate the transcription regulation of SULT1A3. Besides, in certain 
cases such as for PXR, the effect of trans-activation or repression may be determined by 
the ratio of PXR: CAR in the cell (Ding and Staudinger, 2005). Thus, the negative result 
obtained here could be due to the experimental conditions where the ratio of these two 
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receptors may not be optimal. Moreover, the constitutive presence of repressors such as 
NCOR2 that mediates silencing for thyroid and retinoid receptors (Chen and Evans, 1995) 
in the cell could also mask the effect of potential regulatory mechanism, leading to 
negative results. The complexity of the cell, especially the cross-talk between different 
nuclear receptors or pathways, plays a very important role in transcriptional regulation. 
Thus, more studies will be needed before a comprehensive understanding of the 
regulation of SULT1A3 gene can be attained. Such an understanding is of importance as 
SULT1A3 is involved in the metabolism of endogenous compounds as well as exogenous 
molecules, including dopamine, tyramine, and therapeutic molecules such as L-dopa and 
















In this study, putative nuclear receptor binding sites were predicted by using the software 
MatInspector. Various nuclear receptor activators were then tested for their ability to 
induce sulfotransferase1A3 (SULT1A3) promoter activity. Dexamethasone, prednisolone, 
β-napthaflavone and 3-methylcholanthrene were observed to increase the promoter 
activity. Truncation analysis suggested the predicted binding sites were functional. Site-
mutagenesis studies were then used to confirm that these were indeed the critical binding 
sites involved in the promoter activity induction. In addition, over-expression of GR had 
demonstrated that the activation was GR-mediated. In conclusion, an AhR/ARNT (-2795 
to -2773) and a GRE (-1211 to -1193) were found to be involved in the induction of 
SULT1A3 promoter activity by nuclear receptors, and the response to the GRE was 
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Appendix A: Classification of Nuclear Receptors by homology 
Subfamily: name 
Group: name (endogenous ligand if common to entire group)  
Member: name (abbreviation; NRNC Symbol, gene) (endogenous ligand)  
Subfamily 1: Thyroid Hormone Receptor-like 
• Group A: Thyroid hormone receptor (Thyroid hormone)  
o 1: Thyroid hormone receptor-α (TRα; NR1A1, THRA)  
o 2: Thyroid hormone receptor-β (TRβ; NR1A2, THRB)  
• Group B: Retinoic acid receptor (Vitamin A and related compounds)  
o 1: Retinoic acid receptor-α (RARα; NR1B1, RARA)  
o 2: Retinoic acid receptor-β (RARβ; NR1B2, RARB)  
o 3: Retinoic acid receptor-γ (RARγ; NR1B3, RARG)  
• Group C: Peroxisome proliferator-activated receptor (fatty acids, prostaglandins)  
o 1: Peroxisome proliferator-activated receptor-α (PPARα; NR1C1, PPARA)  
o 2: Peroxisome proliferator-activated receptor-β/δ (PPARβ/δ; NR1C2, 
PPARD)  
o 3: Peroxisome proliferator-activated receptor-γ (PPARγ; NR1C3, PPARG)  
• Group D: Rev-ErbA (heme)  
o 1: Rev-ErbAα (Rev-ErbAα; NR1D1)  
o 2: Rev-ErbAβ (Rev-ErbAβ; NR1D2)  
• Group F: RAR-related orphan receptor (cholesterol, ATRA)  
o 1: RAR-related orphan receptor-α (RORα; NR1F1, RORA)  
o 2: RAR-related orphan receptor-β (RORβ; NR1F2, RORB)  
o 3: RAR-related orphan receptor-γ (RORγ; NR1F3, RORC)  
• Group H: Liver X receptor-like (oxysterol)  
o 3: Liver X receptor-α (LXRα; NR1H3)  
o 2: Liver X receptor-β (LXRβ; NR1H2)  
o 4: Farnesoid X receptor (FXR; NR1H4)  
• Group I: Vitamin D receptor-like  
o 1: Vitamin D receptor (VDR; NR1I1, VDR) (vitamin D)  
o 2: Pregnane X receptor (PXR; NR1I2) (xenobiotics)  
o 3: Constitutive androstane receptor (CAR; NR1I3)  
Subfamily 2: Retinoid X Receptor-like 
• Group A: Hepatocyte nuclear factor-4 (HNF4) (fatty acids)  
o 1: Hepatocyte nuclear factor-4-α (HNF4α; NR2A1, HNF4A)  
o 2: Hepatocyte nuclear factor-4-γ (HNF4γ; NR2A2, HNF4G)  
• Group B: Retinoid X receptor (RXRα) (retinoids)  
o 1: Retinoid X receptor-α (RXRα; NR2B1, RXRA)  
o 2: Retinoid X receptor-β (RXRβ; NR2B2, RXRB)  
o 3: Retinoid X receptor-γ (RXRγ; NR2B3, RXRG)  
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• Group C: Testicular receptor  
o 1: Testicular receptor 2 (TR2; NR2C1)  
o 2: Testicular receptor 4 (TR4; NR2C2)  
• Group E: TLX/PNR  
o 1: Human homologue of the Drosophila tailless gene (TLX; NR2E1)  
o 3: Photoreceptor cell-specific nuclear receptor (PNR; NR2E3)  
• Group F: COUP/EAR  
o 1: Chicken ovalbumin upstream promoter-transcription factor I (COUP-
TFI; NR2F1)  
o 2: Chicken ovalbumin upstream promoter-transcription factor II (COUP-
TFII; NR2F2)  
o 6: V-erbA-related gene|V-erbA-related (EAR-2; NR2F6)  
Subfamily 3: Estrogen Receptor-like 
• Group A: Estrogen receptor (Sex hormones: Estrogen)  
o 1: Estrogen receptor-α (ERα; NR3A1, ESR1)  
o 2: Estrogen receptor-β (ERβ; NR3A2, ESR2)  
• Group B: Estrogen related receptor  
o 1: Estrogen-related receptor-α (ERRα; NR3B1, ESRRA)  
o 2: Estrogen-related receptor-β (ERRβ; NR3B2, ESRRB)  
o 3: Estrogen-related receptor-γ (ERRγ; NR3B3, ESRRG)  
• Group C: 3-Ketosteroid receptors  
o 1: Glucocorticoid receptor (GR; NR3C1) (Cortisol)  
o 2: Mineralocorticoid receptor (MR; NR3C2) (Aldosterone)  
o 3: Progesterone receptor (PR; NR3C3, PGR) (Progesterone)  
o 4: Androgen receptor (AR; NR3C4, AR) (Testosterone)  
Subfamily 4: Nerve Growth Factor IB-like 
• Group A: NGFIB/NURR1/NOR1  
o 1: Nerve Growth factor IB (NGFIB; NR4A1)  
o 2: Nuclear receptor related 1 (NURR1; NR4A2)  
o 3: Neuron-derived orphan receptor 1 (NOR1; NR4A3)  
Subfamily 5: Steroidogenic Factor-like 
• Group A: SF1/LRH1  
o 1: Steroidogenic factor 1 (SF1; NR5A1) (phospholipids)  
o 2: Liver receptor homolog-1 (LRH-1; NR5A2)  
Subfamily 6: Germ Cell Nuclear Factor-like 
• Group A: GCNF  
o 1: Germ cell nuclear factor (GCNF; NR6A1)  
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Subfamily 0: Miscellaneous 
• Group B: DAX/SHP  
o 1: Dosage-sensitive sex reversal, adrenal hypoplasia critical region, on 
chromosome X, gene 1 (DAX1, NR0B1)  
o 2: Small heterodimer partner (SHP; NR0B2)  
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